These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25576921)

  • 81. Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma.
    Chen P; Zhao D; Li J; Liang X; Li J; Chang A; Henry VK; Lan Z; Spring DJ; Rao G; Wang YA; DePinho RA
    Cancer Cell; 2019 Jun; 35(6):868-884.e6. PubMed ID: 31185211
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo.
    Denicolaï E; Baeza-Kallee N; Tchoghandjian A; Carré M; Colin C; Jiglaire CJ; Mercurio S; Beclin C; Figarella-Branger D
    Oncotarget; 2014 Nov; 5(21):10934-48. PubMed ID: 25400117
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
    Farmer H; McCabe N; Lord CJ; Tutt AN; Johnson DA; Richardson TB; Santarosa M; Dillon KJ; Hickson I; Knights C; Martin NM; Jackson SP; Smith GC; Ashworth A
    Nature; 2005 Apr; 434(7035):917-21. PubMed ID: 15829967
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition.
    Srikanth M; Das S; Berns EJ; Kim J; Stupp SI; Kessler JA
    Neuro Oncol; 2013 Mar; 15(3):319-29. PubMed ID: 23328812
    [TBL] [Abstract][Full Text] [Related]  

  • 85. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
    Sulkowski PL; Corso CD; Robinson ND; Scanlon SE; Purshouse KR; Bai H; Liu Y; Sundaram RK; Hegan DC; Fons NR; Breuer GA; Song Y; Mishra-Gorur K; De Feyter HM; de Graaf RA; Surovtseva YV; Kachman M; Halene S; Günel M; Glazer PM; Bindra RS
    Sci Transl Med; 2017 Feb; 9(375):. PubMed ID: 28148839
    [TBL] [Abstract][Full Text] [Related]  

  • 86. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
    Chatterjee P; Choudhary GS; Sharma A; Singh K; Heston WD; Ciezki J; Klein EA; Almasan A
    PLoS One; 2013; 8(4):e60408. PubMed ID: 23565244
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.
    Steffen JD; Tholey RM; Langelier MF; Planck JL; Schiewer MJ; Lal S; Bildzukewicz NA; Yeo CJ; Knudsen KE; Brody JR; Pascal JM
    Cancer Res; 2014 Jan; 74(1):31-7. PubMed ID: 24189460
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.
    Zhang N; Tian YN; Zhou LN; Li MZ; Chen HD; Song SS; Huan XJ; Bao XB; Zhang A; Miao ZH; He JX
    Cell Death Dis; 2021 Feb; 12(2):183. PubMed ID: 33589588
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cell context-dependent dual effects of EFEMP1 stabilizes subpopulation equilibrium in responding to changes of in vivo growth environment.
    Hu Y; Ke C; Ru N; Chen Y; Yu L; Siegel ER; Linskey ME; Wang P; Zhou YH
    Oncotarget; 2015 Oct; 6(31):30762-72. PubMed ID: 26307682
    [TBL] [Abstract][Full Text] [Related]  

  • 90. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
    Dedes KJ; Wetterskog D; Mendes-Pereira AM; Natrajan R; Lambros MB; Geyer FC; Vatcheva R; Savage K; Mackay A; Lord CJ; Ashworth A; Reis-Filho JS
    Sci Transl Med; 2010 Oct; 2(53):53ra75. PubMed ID: 20944090
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
    González-Billalabeitia E; Seitzer N; Song SJ; Song MS; Patnaik A; Liu XS; Epping MT; Papa A; Hobbs RM; Chen M; Lunardi A; Ng C; Webster KA; Signoretti S; Loda M; Asara JM; Nardella C; Clohessy JG; Cantley LC; Pandolfi PP
    Cancer Discov; 2014 Aug; 4(8):896-904. PubMed ID: 24866151
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Targeted therapy for brain tumours: role of PARP inhibitors.
    Leonetti C; Biroccio A; Graziani G; Tentori L
    Curr Cancer Drug Targets; 2012 Mar; 12(3):218-36. PubMed ID: 22268386
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
    Ning JF; Stanciu M; Humphrey MR; Gorham J; Wakimoto H; Nishihara R; Lees J; Zou L; Martuza RL; Wakimoto H; Rabkin SD
    Nat Commun; 2019 Jul; 10(1):2910. PubMed ID: 31266951
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
    Wang Z; Grosskurth SE; Cheung T; Petteruti P; Zhang J; Wang X; Wang W; Gharahdaghi F; Wu J; Su N; Howard RT; Mayo M; Widzowski D; Scott DA; Johannes JW; Lamb ML; Lawson D; Dry JR; Lyne PD; Tate EW; Zinda M; Mikule K; Fawell SE; Reimer C; Chen H
    Cancer Res; 2018 Dec; 78(23):6691-6702. PubMed ID: 30297535
    [TBL] [Abstract][Full Text] [Related]  

  • 95. PARP-1 protein expression in glioblastoma multiforme.
    Galia A; Calogero AE; Condorelli R; Fraggetta F; La Corte A; Ridolfo F; Bosco P; Castiglione R; Salemi M
    Eur J Histochem; 2012 Feb; 56(1):e9. PubMed ID: 22472897
    [TBL] [Abstract][Full Text] [Related]  

  • 96. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression.
    Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT
    J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner.
    Lin Y; Kang T; Zhou BP
    Cell Cycle; 2014; 13(11):1708-16. PubMed ID: 24675890
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish.
    Jung IH; Leem GL; Jung DE; Kim MH; Kim EY; Kim SH; Park HC; Park SW
    Neuro Oncol; 2013 Mar; 15(3):290-304. PubMed ID: 23325864
    [TBL] [Abstract][Full Text] [Related]  

  • 99. PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling.
    Hwang E; Yoo KC; Kang SG; Kim RK; Cui YH; Lee HJ; Kim MJ; Lee JS; Kim IG; Suh Y; Lee SJ
    Oncotarget; 2016 Jan; 7(4):4890-902. PubMed ID: 26700818
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.
    Wu S; Wang S; Gao F; Li L; Zheng S; Yung WKA; Koul D
    Neuro Oncol; 2018 Jan; 20(1):78-91. PubMed ID: 29016926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.